Texas Senate Votes to Study Therapeutic Potential of Psychedelics

Texas lawmakers approved legislation over the weekend to study the effectiveness of psychedelics in treating PTSD among veterans and to reduce possession penalties for cannabis concentrates.

Full story after the jump.

The Texas Senate voted over the weekend to study the effectiveness of certain psychedelics in treating veterans with PTSD, according to Marijuana Moment.

Having originated in the Texas House, HB 1802 was amended and passed by the Senate in a 25-5 vote on Sunday and now heads back to the House for final approval. Senate lawmakers also approved a House bill to reduce penalties for the possession of cannabis concentrates.

If passed and ultimately signed into law by the governor, the psychedelics legislation would require the state to partner with Baylor College of Medicine and a military-focused treatment center to study the effectiveness and risks of psilocybin, MDMA, and ketamine in treating veterans with PTSD, according to the report.

Furthermore, the bill would mandate a clinical trial for veterans using psilocybin to treat PTSD and a deeper dive into current literature on the topic.

In an uncharacteristic show of support for drug policy liberalization, former Texas Gov. Rick Perry (R) reportedly championed the bill in the state legislature.

The cannabis concentrates bill seeks to reduce the penalty for possessing up to two ounces of concentrate from a felony to a Class B misdemeanor. If approved, it would be the first time since the 1970s that Texas reduces its penalties for cannabis possession.

Additionally, in a move to regulate Delta 8 THC, senators amended the bill to consider all forms of THC to calculate hemp potency in the state, according to the report.

Get daily cannabis business news updates. Subscribe

Have an additional perspective to share? Send us a message to let us know, and if your comment is chosen by our editors it could be featured here.


Ganjapreneur is made possible by our partners:

Latest Cannabis News

View all news Get email updates

Featured Business Profiles

Create a profile View all categories

From Our Partners